A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.
Kim N. Chi
Consultant or Advisory Role - Janssen
Honoraria - Janssen
Research Funding - Janssen
Thian San Kheoh
Employment or Leadership Position - Janssen
Stock Ownership - Johnson & Johnson
Charles J. Ryan
Honoraria - Janssen
Arturo Molina
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Joaquim Bellmunt
Consultant or Advisory Role - Cougar Biotechnology
Nicholas J. Vogelzang
Consultant or Advisory Role - Amgen; Bayer; Celgene; Cougar Biotechnology; Dendreon; GlaxoSmithKline; Johnson & Johnson; Novartis; Pfizer; Takeda; Veridex
Honoraria - Amgen; Astellas Pharma; Bayer; Cougar Biotechnology; Dendreon; GlaxoSmithKline; Janssen; Johnson & Johnson; Novartis; Pfizer; Sanofi ; Veridex
Research Funding - Algeta; Amgen; Cougar Biotechnology; Johnson & Johnson; Takeda; Veridex
Dana E. Rathkopf
Research Funding - Johnson & Johnson
Karim Fizazi
Consultant or Advisory Role - Janssen
Honoraria - Janssen
Philip W. Kantoff
Consultant or Advisory Role - Janssen
Research Funding - Janssen
Jinhui Li
Employment or Leadership Position - Janssen Research & Development
Johann Sebastian De Bono
Employment or Leadership Position - The Institute of Cancer Research
Consultant or Advisory Role - Astellas Pharma; Johnson & Johnson; Medivation
Honoraria - Astellas Pharma; Johnson & Johnson; Medivation
Howard I. Scher
Consultant or Advisory Role - Aragon Pharmaceuticals (U); Bristol-Myers Squibb; Celgene (U); Dendreon; Endo/Orion Pharmaceuticals; Exelixis (U); Foundation Medicine (U); Genentech; Janssen (U); Johnson & Johnson (U); Medivation (U); Millennium (U); Novartis; Ortho Biotech; Sanofi ; Senior Scientific; Takeda (U)
Research Funding - Aragon Pharmaceuticals; Bristol-Myers Squibb; Exelixis; Janssen; Janssen Research & Development; Medivation